Assessment
capivasertib
ER-positive, HER2-negative locally advanced or metastatic breast cancer with PIK3CA/AKT1/PTEN alterations after recurrence or progression during or after endocrine therapy
- Modules
- IQWiG assessments · G-BA decisions
- Connections
- 2
Connected evidence
2 relations